- Home
- MVST vs PCRX Comparison
MVST vs PCRX Comparison
Compare MVST & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | PCRX |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 1.0B |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | MVST | PCRX |
|---|---|---|
| Price | $1.46 | $23.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 4.7M | 516.5K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $24.55 | $6.78 |
| Revenue Next Year | $17.08 | $8.54 |
| P/E Ratio | ★ N/A | $336.29 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $1.17 | $18.80 |
| 52 Week High | $7.12 | $27.64 |
Technical Indicators
Market Signals| Indicator | MVST | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 49.85 |
| Support Level | N/A | $22.13 |
| Resistance Level | $2.16 | $24.20 |
| Average True Range (ATR) | 0.15 | 1.02 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 29.71 | 42.93 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.